Xiaosu Ma

Xiaosu Ma

Eli Lilly and Company - Indianapolis / United States
Medical and Health Sciences / Pharmacy & Pharmaceutical Sciences
AD Scientific Index ID: 4384665
-
person_outline Xiaosu Ma's MOST POPULAR ARTICLES
1-) Are we optimizing gestational diabetes treatment with glyburide? The pharmacologic basis for better clinical practiceMF Hebert, X Ma, SB Naraharisetti, KM Krudys, JG Umans, GDV Hankins, ...Clinical Pharmacology & Therapeutics 85 (6), 607-614, 20092222009
2-) Daily oral GLP-1 receptor agonist orforglipron for adults with obesityS Wharton, T Blevins, L Connery, J Rosenstock, S Raha, R Liu, X Ma, ...New England Journal of Medicine 389 (10), 877-888, 2023872023
3-) Lepodisiran, an extended-duration short interfering RNA targeting lipoprotein (a): a randomized dose-ascending clinical trialSE Nissen, H Linnebjerg, X Shen, K Wolski, X Ma, S Lim, LF Michael, ...Jama 330 (21), 2075-2083, 2023952023
4-) Obstetric-Fetal Pharmacology Research Unit Network. Are we optimizing gestational diabetes treatment with glyburide? The pharmacologic basis for better clinical practiceMF Hebert, X Ma, SB Naraharisetti, KM Krudys, JG Umans, GD Hankins, ...Clin Pharmacol Ther 85 (6), 607-614, 2009932009
5-) Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 studyJP Frias, S Hsia, S Eyde, R Liu, X Ma, M Konig, C Kazda, KJ Mather, ...The Lancet 402 (10400), 472-483, 2023822023